The unfolded protein response: from stress pathway to homeostatic regulation, Galway, Galway H91 TK33, Ireland. 4 2bind GmbH, vol.11, pp.1081-1086, 2011. ,
An unfolded protein-induced conformational switch activates mammalian IRE1, Elife, vol.6, p.30700, 2017. ,
ER stress-induced cell death mechanisms, Biochim. Biophys. Acta, vol.1833, pp.3460-3470, 2013. ,
Regulated translation initiation controls stress-induced gene expression in mammalian cells, Mol. Cell, vol.6, pp.1099-1108, 2000. ,
Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), J. Med. Chem, vol.55, pp.7193-7207, 2012. ,
Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity, Cell Death Dis, vol.6, p.1672, 2015. ,
When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157, Cell Death Differ, vol.24, pp.1100-1110, 2017. ,
Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress, Cell, vol.158, pp.534-548, 2014. ,
Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity, J. Med. Chem, vol.57, pp.4289-4301, 2014. ,
C-KITsignaling in cancer treatment, Curr. Pharm. Des, vol.20, pp.2849-2880, 2014. ,
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9, Nat. Biotechnol, vol.34, pp.184-191, 2016. ,
Multiplex genome engineering using CRISPR/Cas systems, Science, vol.339, pp.819-823, 2013. ,
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor, Proc. Natl. Acad. Sci. USA, vol.110, pp.5689-5694, 2013. ,
PERK inhibition attenuates the abnormalities of the secretory pathway and the increased apoptotic rate induced by SIL1 knockdown in HeLa cells, Biochim. Biophys. Acta, vol.1864, pp.3164-3180, 2018. ,
Effects of PERK eIF2alpha kinase Inhibitor against Toxoplasma gondii, Antimicrob. Agents Chemother, vol.62, pp.1442-1460, 2018. ,
PERK regulates glioblastoma sensitivity to ER stress although promoting radiation resistance, Mol. Cancer Res, vol.16, pp.1447-1453, 2018. ,
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor, Blood, vol.96, pp.925-932, 2000. ,
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase, J. Biol. Chem, vol.279, pp.31655-31663, 2004. ,
Molecular and functional characterization of a new 3? end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant imatinib, Oncotarget, vol.8, pp.56158-56167, 2017. ,
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study, Blood, vol.123, pp.2317-2324, 2014. ,
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies, Cancer Res, vol.66, pp.473-481, 2006. ,
Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK), J. Med. Chem, vol.58, pp.1426-1441, 2015. ,
PERK is a haploinsufficient tumor suppressor: gene dose determines tumor-suppressive versus tumor promoting properties of PERK in melanoma, PLoS Genet, vol.12, p.1006518, 2016. ,
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects, Blood, vol.107, pp.752-759, 2006. ,
C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCdelta translocation in HMC-1(560) and HMC-1(560,816) cell lines, Immunopharmacol. Immunotoxicol, vol.37, pp.380-387, 2015. ,
BI 1002494, a novel potent and selective oral spleen tyrosine kinase inhibitor, displays differential potency in human basophils and B cells, J. Pharmacol. Exp. Ther, vol.357, pp.554-561, 2016. ,
SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain, Mol. Cell. Biol, vol.18, pp.2089-2099, 1998. ,
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells, PLoS ONE, vol.7, p.40853, 2012. ,
Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors, Am. J. Physiol. Cell Physiol, vol.297, pp.591-600, 2009. ,
The EGFR odyssey-from activation to destruction in space and time, J. Cell Sci, vol.130, pp.4087-4096, 2017. ,
Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide, Oncogene, vol.32, pp.1018-1029, 2013. ,
Met receptor: a moving target, Sci. Signal, vol.4, p.40, 2011. ,
Clathrin assembly protein CALM plays a critical role in KIT signaling by regulating its cellular transport from early to late endosomes in hematopoietic cells, PLoS ONE, vol.9, p.109441, 2014. ,
Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain, Oncogene, vol.21, pp.4508-4520, 2002. ,
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death, Sci. Rep, vol.7, p.15278, 2017. ,
Targeting ABL-IRE1alpha signaling spares ER-stressed pancreatic beta cells to reverse autoimmune diabetes, Cell Metab, vol.25, pp.883-897, 2017. ,